Potential Usefulness of Bone Densitometry in the Follow Up of Patients with Fibrous Dysplasia Treated with Bisphosphonates

M.S. PARISI; M.B. OLIVERI,; C GÓMEZ ACOTTO; C MAUTALEN

TORONTO

Congreso; XXII CONGRESO ANUAL DE LA ASBMR; 2000

ASBMR

Presentation Number: M105The aim of this study was to evaluate the usefulness of Total Body (TB) densitometry and the ROIanalysis of affected areas in patients with Fibrous Dysplasia (FD). Eleven out of 21 patients diagnosedwith FD were selected for the study and treated with intravenous pamidronate (APD), 60 mg/day for 3days every 6 months (still in progress). Mean age of the study population was 32.6 years (range: 13-79).A complete clinical, biochemical and radiographic evaluation was performed. Bone mineral density(BMD) of TB and different sub areas was assessed by dual photon absorptiometry (Lunar EXPERT) atbaseline and once a year. In patients with unilateral location of the disease, FD areas (FDA) delimited byROI analysis were compared with their contralateral non-affected side (CNA). The difference in BMDwas calculated as a percentage where the healthy side was taken as 100%.At baseline TB BMD values were in the normal ranges, except one postmenopausal woman withdiminished BMD. The mean difference between FDA and CNA (5 located in the arms, 5 in legs and 1 inpelvis) was -10.9 % (range: -37.5 to +4.4). Follow up of 2 patients showed 3.4% and 1.2% increments ofTB BMD while BMD of FDA increased 6.3% and 9.5% respectively.Whereas TB BMD was mostly within normal ranges, BMD of FDA was lower than the correspondinghealthy contralateral side. Treatment with I-V APD produces an increase in FDA BMD. It can thereforebe concluded that TB densitometry and ROI analysis of FDA may be useful to evaluate bone involvementand to monitor medical treatment in FD patients